- Home
- TR vs VERA Comparison
TR vs VERA Comparison
Compare TR & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TR
- VERA
- Stock Information
- Founded
- TR 1896
- VERA 2016
- Country
- TR United States
- VERA United States
- Employees
- TR N/A
- VERA N/A
- Industry
- TR Specialty Foods
- VERA Biotechnology: Pharmaceutical Preparations
- Sector
- TR Consumer Staples
- VERA Health Care
- Exchange
- TR Nasdaq
- VERA Nasdaq
- Market Cap
- TR 2.2B
- VERA 1.8B
- IPO Year
- TR N/A
- VERA 2021
- Fundamental
- Price
- TR $32.64
- VERA $28.82
- Analyst Decision
- TR
- VERA Buy
- Analyst Count
- TR 0
- VERA 8
- Target Price
- TR N/A
- VERA $65.50
- AVG Volume (30 Days)
- TR 136.1K
- VERA 1.1M
- Earning Date
- TR 04-24-2025
- VERA 02-26-2025
- Dividend Yield
- TR 1.09%
- VERA N/A
- EPS Growth
- TR N/A
- VERA N/A
- EPS
- TR 1.18
- VERA N/A
- Revenue
- TR $723,217,000.00
- VERA N/A
- Revenue This Year
- TR N/A
- VERA N/A
- Revenue Next Year
- TR N/A
- VERA N/A
- P/E Ratio
- TR $27.56
- VERA N/A
- Revenue Growth
- TR N/A
- VERA N/A
- 52 Week Low
- TR $26.78
- VERA $25.99
- 52 Week High
- TR $33.01
- VERA $51.61
- Technical
- Relative Strength Index (RSI)
- TR 65.79
- VERA 39.36
- Support Level
- TR $29.61
- VERA $27.55
- Resistance Level
- TR $31.48
- VERA $30.51
- Average True Range (ATR)
- TR 0.88
- VERA 1.79
- MACD
- TR 0.21
- VERA 0.29
- Stochastic Oscillator
- TR 100.00
- VERA 57.08
About TR Tootsie Roll Industries Inc.
Tootsie Roll Industries Inc manufactures and sells confectionery products. Notable varieties include Tootsie Roll and Tootsie Pops, Charms, Blow-Pops, Dots, Junior Mints, Sugar Daddy and Sugar Babies, Andes, Dubble Bubble, Razzles among others. The company sells its products to wholesale distributors and directly to retail stores. Geographically, it generates a majority of its revenue from the United States and rest from Canada, Mexico and other regions.
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.